DUPIXENT DEMONSTRATED HISTOLOGIC REMISSION
IN CHILDREN AGED 1-11 YEARS1,2
HISTOLOGIC REMISSION ACHIEVED: 66% AT WEEK 16 AND 53% AT WEEK 52
Histologic Remission1,2
(<6 EOS/HPF peak esophageal
intraepithelial EOS count)
Histologic Remission1,2
(<6 EOS/HPF peak esophageal
intraepithelial EOS count)
Histologic Remission1,2
(≤6 EOS/HPF peak esophageal
intraepithelial EOS count)
- 100
- 50
- 0
EoE KIDS-Part A
Primary Endpoint WEEK 52
EoE KIDS-Part B
Secondary Endpoint
DUPIXENT
(n=32)
Placebo
(n=29)
DUPIXENT
(n=32)
Switch to
DUPIXENT
(n=15)
Histologic Response1,2
(<15 EOS/HPF peak esophageal
intraepithelial EOS count)
- 100
- 50
- 0
EoE KIDS-Part A
Secondary Endpoint WEEK 52
EoE KIDS-Part B
Secondary Endpoint
DUPIXENT
(n=32)
Placebo
(n=29)
DUPIXENT
(n=32)
Switch to
DUPIXENT
(n=15)
Results are descriptive in the extended active treatment period at Week 52. Definitive conclusions cannot be made due to limitations associated with extended active treatment design, including lack of comparator arm and decreasing sample size.
Peak Esophageal
Intraepithelial
Eosinophil Count3,4
Used to confirm diagnosis and
determine treatment response. Histologic data
are reported as the percentage of
patients achieving the defined EOS threshold.
EOS, eosinophil: EOS/HPF, eosinophils per high-power field.